Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia

The treatment of Ph-positive acute lymphoblastic leukemia (Ph+ ALL) has entranced tyrosine kinase inhibitors (TKIs) era. Currently both imatinib and dasatinib are registered as the front-line treatment for Ph+ ALL, and the other 2(nd)-generation TKIs are suggested as an alternative for those who fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guopan, Chen, Fang, Yin, Changxin, Liu, Qifa, Sun, Jing, Xuan, Li, Fan, Zhiping, Wang, Qiang, Liu, Xiaoli, Jiang, Qianli, Xu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739793/
https://www.ncbi.nlm.nih.gov/pubmed/29291008
http://dx.doi.org/10.18632/oncotarget.22206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739793/
https://www.ncbi.nlm.nih.gov/pubmed/29291008
http://dx.doi.org/10.18632/oncotarget.22206

Ejemplares similares